Dublin, Jan. 23, 2024 (GLOBE NEWSWIRE) -- The "Hepatitis B Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033" report has been added to ResearchAndMarkets.com's offering.
The healthcare industry is poised to observe substantial growth in the Hepatitis B diagnostics space, according to the latest market research report. An expansive forecast provides insights into the future of the Hepatitis B Tests market through 2033, encompassing in vitro diagnostics within its investigative parameters. The report diligently reviews the multifaceted domain, which has been significantly influenced by the COVID-19 pandemic throughout 2020 and beyond.
Hepatitis B is a common cause of liver disease across the globe, and remains a major issue for most of the governments despite the fact that an effective vaccine has been available since 1982. The World Health Organization (WHO) recommends that all infants receive the hepatitis B vaccination and universal vaccinations have now been implemented in numerous countries worldwide. Screening of pregnant women for HBV is standard of care in most countries and considered to be a cost-effective strategy for reducing the risk of transmission to the baby. Women are typically screened during their first trimester of pregnancy. For pregnant women at high-risk of acquiring HBV, testing is sometimes repeated at the beginning of the third trimester (28 weeks) or at the time of delivery.
HBV tests are performed for a number of purposes:
- screening of suspected infection patients and diagnosis;
- monitoring of HBV-positive patients;
- screening or pregnant women; and
- screening of donors of human cells, tissues, and cellular and tissue-based products (HCT/P).
The Hepatitis B Virus Tests includes Hepatitis B Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Hepatitis B Nucleic Acid Amplification Tests (NAATs) and Multi-parameter HIV, Hepatitis B, and Hepatitis C NAATs.
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed Hepatitis B Tests and evolving competitive landscape:
- Insightful review of the key industry trends.
- Annualized total Hepatitis B Tests market revenue by segment and market outlooks from 2015-2033.
- Market level data on units, average selling prices and market values.
Global, Regional and Country level market specific insights:
- Qualitative market specific information is available with global trends further broken down into regional trends. In addition, The analysts provide unique country specific insights on the market.
- SWOT analysis for Hepatitis B Tests market.
- Competitive dynamics insights and trends provided for Hepatitis B Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country specific overview of the healthcare system.
- Country specific reimbursement policies.
- Country specific medtech regulatory landscape.
The model will enable you to -
- Understand the impact of COVID-19 on Hepatitis B Tests market.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving Hepatitis B Tests market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Hepatitis B Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counterstrategies to gain a competitive advantage.
- Track device sales in the global and country-specific Hepatitis B Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
A selection of companies mentioned in this report includes
- Abbott Laboratories
- Bio-Rad Laboratories Inc
- Hologic Inc
- Quidelortho Corp
- Oswaldo Cruz Foundation
- Grifols SA
- F. Hoffmann-La Roche Ltd
- Siemens AG
- Qiagen NV
- biomerieux SA
- DiaSorin SpA
For more information about this report visit https://www.researchandmarkets.com/r/97dzn1
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
